- Home
- MCRI vs NRIX Comparison
MCRI vs NRIX Comparison
Compare MCRI & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MCRI
- NRIX
- Stock Information
- Founded
- MCRI 1972
- NRIX 2009
- Country
- MCRI United States
- NRIX United States
- Employees
- MCRI N/A
- NRIX N/A
- Industry
- MCRI Hotels/Resorts
- NRIX Biotechnology: Pharmaceutical Preparations
- Sector
- MCRI Consumer Discretionary
- NRIX Health Care
- Exchange
- MCRI Nasdaq
- NRIX Nasdaq
- Market Cap
- MCRI 1.5B
- NRIX 908.0M
- IPO Year
- MCRI 1993
- NRIX 2020
- Fundamental
- Price
- MCRI $87.98
- NRIX $12.73
- Analyst Decision
- MCRI Hold
- NRIX Strong Buy
- Analyst Count
- MCRI 5
- NRIX 16
- Target Price
- MCRI $88.60
- NRIX $30.44
- AVG Volume (30 Days)
- MCRI 97.4K
- NRIX 747.9K
- Earning Date
- MCRI 07-23-2025
- NRIX 07-10-2025
- Dividend Yield
- MCRI 1.34%
- NRIX N/A
- EPS Growth
- MCRI N/A
- NRIX N/A
- EPS
- MCRI 3.96
- NRIX N/A
- Revenue
- MCRI $525,923,000.00
- NRIX $56,417,000.00
- Revenue This Year
- MCRI $4.32
- NRIX $16.69
- Revenue Next Year
- MCRI $2.41
- NRIX N/A
- P/E Ratio
- MCRI $22.66
- NRIX N/A
- Revenue Growth
- MCRI 3.84
- NRIX N/A
- 52 Week Low
- MCRI $65.65
- NRIX $8.18
- 52 Week High
- MCRI $96.11
- NRIX $29.56
- Technical
- Relative Strength Index (RSI)
- MCRI 72.59
- NRIX 62.83
- Support Level
- MCRI $85.71
- NRIX $11.34
- Resistance Level
- MCRI $90.02
- NRIX $12.90
- Average True Range (ATR)
- MCRI 1.93
- NRIX 0.66
- MACD
- MCRI 0.37
- NRIX 0.02
- Stochastic Oscillator
- MCRI 92.35
- NRIX 90.17
About MCRI Monarch Casino & Resort Inc.
Monarch Casino & Resort Inc is engaged in providing the latest gaming, dining, and hospitality amenities. It owns and operates the Atlantis Casino Resort Spa, a hotel/casino facility in Reno, Nevada, and the Monarch Black Hawk Casino in Black Hawk. The company generates the majority of its revenue from Casinos, followed by Food & Beverage and Hotel Operations.
About NRIX Nurix Therapeutics Inc. Common stock
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.